Thrombosis and Bleeding



Similar documents
Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

Time of Offset of Action The Trial

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Anticoagulation Therapy Update

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

New Oral Anticoagulants. How safe are they outside the trials?

Daily aspirin therapy: Understand the benefits and risks

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

DVT/PE Management with Rivaroxaban (Xarelto)

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Antiplatelet and Antithrombotics From clinical trials to guidelines

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

ABOUT XARELTO CLINICAL STUDIES

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

The Role of the Newer Anticoagulants

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

New Anticoagulants and GI bleeding

Anticoagulation at the end of life. Rhona Maclean

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

East Kent Prescribing Group

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

STROKE PREVENTION IN ATRIAL FIBRILLATION

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

New Anticoagulants: What to Use What to Avoid

23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Cardiovascular Disease

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Anticoagulants in Atrial Fibrillation

Blood-thinning medication after stroke

The author has no disclosures

THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS

9/5/14. Objectives. Atrial Fibrillation (AF)

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Thrombosis and Hemostasis

How To Treat Aneuricaagulation

Treatments to Restore Normal Rhythm

More information for patients and caregivers can be accessed at

New Oral AntiCoagulants (NOAC) in 2015

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

TSOAC Initiation Checklist

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

Therapeutic Class Overview Oral Anticoagulants

2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

New Oral Anticoagulants

Clinical Practice Guideline for Anticoagulation Management

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

OAC and NOAC with or without platelet inhibition

NHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY

GRASP-AF Coming to a PCT near you.

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

Dabigatran (Pradaxa) Guidelines

6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare

Breadth of indications matters One drug for multiple indications

An#- Coagulant An#- Thrombo#c An#- Platelet Drugs

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Rivaroxaban (Xarelto ) by

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Stepping Beyond Warfarin:

Investor News. Not intended for U.S. and UK media

Critical Bleeding Reversal Protocol

What You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist

Anticoagulation For Atrial Fibrillation

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

Bios 6648: Design & conduct of clinical research

Transcription:

Many questions, few answers Thrombosis and Bleeding Pierre Noel MD Mayo Arizona

Scope of the Problem Thrombosis PV 12-39% ET 11-25% MF 10% 60-70% of thrombosis are arterial Splanchnic and cerebral thrombosis are more common Bleeding PV <10% ET 10-15% MF 15-20%

Why do we clot excessively? Platelet number? Activated platelets Increased hemoglobin Increased leukocytes JAK2V617F allele burden Inflammation CRP, Pentraxin 3 Decreased protein S (platelet proteases) Abnormal lining of blood vessels (Endothelium) Decreased NO in ET

Why do we bleed excessively? Decreased platelet granules Abnormal aggregation of platelets Increased breakdown of Von Willebrand molecule by ADAMTS13 Related to platelet count

Tefferi. Hemostasis and Thrombosis.LWW. 2013 Treatment Algorithm Risk Category ET PV Management Pregnancy Low-risk Platelets < 1 M <60 No thrombosis hist. Low risk Platelets> 1 M High-risk Age>60 History Thrombosis High-risk refractory or intolerant to HU Low-dose ASA Low-dose ASA if risto cofactor activity >30% Low-dose ASA Phlebotomy Ht<45 Low-dose ASA if risto cofactor activity >30% + phelbotomy Low-dose ASA + HU Low-dose ASA + phlebotomy +HU Low-dose ASA + IFNα (<65) or busulfan (>65) Low-dose ASA + phlebotomy + IFNα (<65) or busulfan (>65) Low-dose ASA + Phlebotomy if PV Low-dose ASA if risto cofactor activity >30% + phlebotomy if PV Low-dose ASA + phlebotomy if PV + IFN-alpha Low-dose ASA + phlebotomy if PV+ IFN-α

Aspirin THROMBOSIS BLEEDING

From: The Role of Aspirin in Cardiovascular Prevention: Title and subtitle BreakImplications of Aspirin Resistance J Am Coll Cardiol. 2008;51(19):1829-1843. doi:10.1016/j.jacc.2007.11.080 Aspirin works by irreversibly inhibiting cyclooxygenase-1 (COX-1) on platelets, thereby reducing the production of thromboxane A2. Figure Legend: Inhibition of Platelet Thromboxane A2 Pathways by Low-Dose Aspirin Figure illustration by Rob Flewell. Date of download: 2/6/2013 Copyright The American College of Cardiology. All rights reserved.

Primary prevention Antithrombotic Trialists Collaboration Aspirin for primary prevention Metaanalysis Healthy volunteers Rates of thrombosis= 5.4/1000 person-years Reduction in thrombotic events 0.51%/y aspirin vs 0.57%/y controls (p=0.0001) Increase in GI and extracranial bleeds 0.1%/y aspirin vs 0.07%/y controls (p=0.0001) Baigent et al. Lancet, 2009.

Primary prevention I don t tolerate ASA 81 mg very well, it gives me heartburn, can I take Plavix instead? MPNs are associated with excessive thromboxane production. ASA impacts thromboxane production. No published data comparing ASA and Plavix in primary prevention Take ASA with food, consider proton pump inhibitor. Cumulative incidence of recurrent GI ulcer bleeding at 1 year is 8.6% with Plavix and 7.9% with aspirin and omeprazole (Chan FK et al, NEJM, 2005)

Primary Prevention Can I take ASA 325 mg instead of a baby aspirin (81 mg)? Majority of MPN studies were performed at doses <100 mg Risk of bleeding is 3X increased >200 mg/day

Primary Prevention I have an aspirin allergy, should I take Plavix? Role of Plavix in MPN primary prevention has not been studied. Not unreasonable. I have ET and am quite concerned about my risk of getting a stroke, can I use ASA 81 mg/day + Plavix 75 mg/day? No data for primary prevention Data from ISCALP study is not out (study closed) Risk of bleeding is at least 2X increased

Secondary prevention I had a recent TIA which lead to my diagnosis of ET. Should I receive ASA + Plavix? No specific data for MPN patients In non MPN patients the combination of ASA 81mg/ day + extended release dipyridamole 200 mg twice appears to be superior to ASA 81 mg alone. Indications of combined ASA + Plavix Acute coronary syndrome Drug eluting stent Bare metal stent

Aspirin resistance True resistance is rare! Compliance (50%) Competition for COX-1 binding site from ibuprofen and naproxen Increased platelet turnover (diabetes, cardiac surgery) Obesity (leptins increase platelet reactivity) Aspirin enteric coating Impaired sensitivity to COX-1 COX-1 polymorphisms Stimulation of platelets by ASA insensitive mechanisms www.neurology.org

Secondary Prevention I had a TIA while taking ASA and Hydroxyurea, should I add Plavix? Commonly done (viewed by many as standard of care) Evidence of benefit in PV and ET is not proven Increases risk of bleeding (specially in patients >70 y) Role of ASA 325 mg once a day or 81 mg twice a day is unclear. I am a 47 yo male with ET, taking ASA 81 mg/d, I had a TIA last week, what should I do? Consider initiating cytoreductive therapy Consider adding Plavix

Secondary Prevention Seventy year old patient with PV, treated with phlebotomies + ASA + hydroxyurea develops a deep venous thrombosis or atrial fibrillation (AF). What is the best treatment? Best treatment for AF is anticoagulation with warfarin or dabigatran (Pradaxa ) or rivaroxaban (Xarelto ) Best treatment for DVT is anticoagulation with either warfarin or rivaroxaban (Xarelto ). Warfarin, rivaroxaban, dabigatran may not provide optimal prophylaxis for arterial thrombotic events (?), ASA may need to be added

Combination Therapy United Kingdom General practice Research database- 70,760 patients with Atrial Fibrillation. Risk of bleeding Warfarin RR 2.08 Clopidrogrel RR 1.57 Aspirin RR 1.25 Warfarin +ASA RR 2.87 Warfarin + clopidogrel RR 2.74 ASA + Clopidogrel RR 1.68 Triple Therapy RR 3.75 Azoulay et al. Thromb Haemost, 2013.

Hormone replacement and oral contraceptives I am a 34 yo woman with ET. I am on ASA 81 mg/ day. Can I take an oral contraceptive? Retrospective study demonstrated an increased risk of venous thrombosis (Gangat et a. Cancer, 2006) I am a 52 yo woman with ET. I would like to be on hormone replacement therapy. Is there any data? Retrospective data did not demonstrate increased risk of thrombosis (Gangat et a. Cancer, 2006)

Hormone replacement and oral contraceptives I am a 32 yo woman with PV, would like to be on an oral contraceptive. Advice PV is a risk factor for thrombosis Oral contraceptives : risk factor for thrombosis Level of protection provided by ASA? Prior history of thrombosis? Family history of thrombosis? Thrombophilia?

Bleeding 43 year old man with ET. No history of prior thrombosis. Platelet count of 1.35 million. Treated with ASA 81 mg/day. Presents with recurrent nosebleeds. Platelet aggregation study is abnormal ASA + ET Von Willebrand activity is decreased to 25% Recommend: D/C aspirin Arbitrary threshold to start HU is 1.5 M

Bleeding 43 year old man with ET. No history of prior thrombosis. Platelet count of 1.35 million. Treated with ASA 81 mg/day. Presents with recurrent nosebleeds. Patient develops left quadrant pain and requires surgery for diverticulitis. Options: 1- Pheresis < 800,000 2- Desmopressin 0.3 mcg/kg IV(VW short ½ life) 3- Cryoprecipitate or antihemophilic factor/von Willebrand complex (Alphanate, Humate-P )

Bleeding 78 yo man with history of coronary artery disease and PV, requires a total hip arthroplasty. His hematocrit is 51, his WBC is 12,000 and his platelet count is 1.1 million. He is on ASA 81 mg/day and takes HU intermittently. Pre-op recommendations: Hematocrit <45 Platelet count < 400,000 Post-op recommendations: Low-molecular heparin for 35 days Hold aspirin Hydroxyurea +/- phlebotomies (Ht <45)

Bleeding 67 year old woman with history of coronary heart disease and myelofibrosis, develops painful splenomegaly following portal vein thrombosis. Following splenectomy her platelet count rises > 1.4 M she develops a severe gastrointestinal bleed. 20% develop thrombocytosis post-splenectomy Mortality 20% (2/3 thrombosis, 1/3 GI bleeding) Options: Red cell transfusions Platelet pheresis Desmopressin (increased thrombotic risk) VW complex or cryoprecipitate

Thank you!